NCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT05333874 2026-02-09
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Active not recruiting
NCT07262138 2025-12-03
ACTIVE
University of Pittsburgh
Recruiting
NCT03418961 2025-10-08
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04625023 2025-05-01
METAMECH
IFOM ETS - The AIRC Institute of Molecular Oncology
Recruiting